Evidence map›Paper›PMID 31767717›Full record

Trial reportAntimicrobial agents and chemotherapy2020

E Wenzler, K M Meyer, S C Bleasdale, M Sikka, R E Mendes, K L Bunnell, M Finnemeyer, S L Rosenkranz, L H Danziger, K A Rodvold

Open access · greenAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Bacteriological and molecular study of fosfomycin resistance in uropathogenic Escherichia coli.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  2. Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  3. Article
  4. Studies on Virulence and Extended-SpectrumBioMed research international · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

E WenzlerCollege of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID 0000-0003-3914-8400
K M MeyerCollege of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
S C BleasdaleCollege of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
M SikkaCollege of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.
R E MendesJMI Laboratories, North Liberty, Iowa, USA.
K L BunnellCollege of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID 0000-0002-7646-0594
M FinnemeyerHarvard TH Chan School of Public Health, Boston, Massachusetts, USA.
S L RosenkranzHarvard TH Chan School of Public Health, Boston, Massachusetts, USA.
L H DanzigerCollege of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
K A RodvoldCollege of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA kar@uic.edu.
University of Illinois Chicago · USHarvard University · USJMI Laboratories · US

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
Strengthening Stakeholder Engagement in Human Research Protections.UL1TR002003 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KARNIK, NIRANJAN SUBHASH, MERMELSTEIN, ROBIN J. · 2016 to 2024
$33.7M
NCATS NIH HHS UL1 TR002003NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

The

Indexed as

AdultAnti-Bacterial AgentsCross-Over StudiesEscherichia coliFemaleFosfomycinHealthy VolunteersHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsProteus mirabilisUrinary TractUrinary Tract InfectionsAnti-Bacterial AgentsFosfomycinfosfomycinpharmacodynamicsurinary bactericidal titersurinary tract infectionurine

Identifiers

PMID31767717
PMCPMC6985713
OpenAlexW2991488880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.